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Case presentation
A 64-year-old man was admitted to the hospital for evaluation of
progressive dyspnea and increasing angina. The medical history was
significant for coronary artery disease with an uncomplicated myocar-
dial infarction 8 years ago. Diabetes was diagnosed 10 years ago and
was controlled currently with diet alone. Peripheral vascular disease
necessitated a left below-the-knee amputation 2 years ago. Although
previously a "heavy" smoker, he had stopped smoking 5 years ago.
Current medications included furosemide, persantine, and digoxin.
Physical examination revealed a blood pressure of 120/76 mm Hg;
pulse, 82 beats/mm and regular; and respirations, 24/mm. No jugular
venous distension was present. The chest had bibasilar rales. Cardiac
examination was unremarkable. There was no abdominal organome-
galy. External genitalia and rectal examination were unremarkable, A
sensory-motor peripheral neuropathy was present.
Laboratory data on admission included: sodium, 138 mEq/liter;
potassium, 5.5 mEq/liter; chloride, 109 mEq/Iiter; and carbon dioxide,
22 mEq/liter. The BUN was 68 mg/dl and the creatinine 3.8 mgldl.
Glucose was 123 mg/dl. Urinalysis revealed 3+ albumin, trace glucose,
6—9 white blood cells/high-power field, and no casts. An electrocardio-
gram showed normal sinus rhythm and evidence of an old, anteroseptal
myocardial infarction. A plain chest film disclosed small bilateral
pleural effusions and changes of chronic obstructive pulmonary disease.
Renal ultrasound examination was normal. The 24-hour creatinine
clearance was 26 mI/mm. Urine protein excretion was 5.8 g/24 hours.
The patient was scheduled for coronary angiography. Prior to angi-
ography he received 1000 ml of 0.45% saline over 10 hours, which was
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followed by 200 ml of 20% mannitol over 3 hours. lopamidol (Isovue,
Squibb), 140 cc, was administered, and furosemide, 40 mg, was given
intravenously immediately upon completion of the angiographic proce-
dure. The procedure revealed severe proximal stenosis of the left
anterior descending and circumflex coronary arteries. A dominant right
coronary artery had only a mild proximal stenosis.
In the 24 hours after angiography, his urine output was 1800 cc.
Intravenous 0.45% saline was administered to replace urinary losses.
On the first day after the angiogram, the creatinine was 5.5 mg/dl.
Oliguria did not occur, but the serum creatinine rose to 6.4 mg/dl on the
second day. Over the next several days, the serum creatinine concen-
tration gradually fell, and 6 days after the angiogram it was 3.5 mg/dl.
Eight days after having the angiogram, the patient was scheduled for
percutaneous transluminal coronary angioplasty (PTCA). Intravenous
0.45% saline and mannitol were given again according to the previous
protocol, and 360 cc of iopamidol was administered. Within 24 hours of
successful two-vessel PTCA, the patient became oliguric. Furosemide,
metolazone, and low-dose dopamine, 2 zg/kg/min, were administered
without response. On the first day following the angioplasty, the
creatinine rose to 6.9 mg/dl. Six days after angioplasty, the creatinine
peaked at 8.3 mg/dl. On the seventh day, urine output abruptly rose to
3000 cc/24 hours, and the serum creatinine began to fall. Two weeks
after angioplasty, the patient was discharged with a stable serum
creatinine of 4.0 mg/dl.
Discussion
DR. ARNOLD S. BERNS (Attending Physician, Michael Reese
Hospital and Medical Center, and Assistant Clinical Professor
of Medicine, Pritzker School of Medicine, University of Chi-
cago, Chicago, Illinois): In the modern era of invasive diagnos-
tic and therapeutic medicine, we now recognize contrast-
associated nephropathy as an important cause of renal failure.
Indeed, one recent review of hospital-acquired acute renal
failure documented that radiocontrast agents accounted for 12%
of episodes of renal failure and that these agents exceeded
aminoglycoside antibiotics in nephrotoxic potential [1]. Early
studies reported sporadic cases of oliguric renal failure follow-
ing the administration of di-iodinated contrast material used for
either excretory urography or aortography [2—7]. These reports
prompted some authors to suggest that procedures requiring
contrast media should be prohibited in patients with preexisting
renal insufficiency. But tri-iodinated compounds with greater
water solubility became available, and several studies demon-
strated the safety of these agents (at least in the relatively low
dosages employed) and endorsed their use, even for patients
with advanced renal insufficiency [8, 9]. With the expanding use
of synthetic, tri-iodinated compounds—for the most part the
sodium or meglumine salts of diatrizoate—well-documented
case reports of both reversible and irreversible acute renal
failure following excretory urography, drip-infusion urography,
and arteriography began to appear [10—15].
730
Editors
JORDAN J. COHEN
JOHN T. HARRINGTON
JEROME P. KASSIRER
NICOLAOS E. MADIAS
Managing Editor
CHERYL J. ZUSMAN
State University of New York at Stony Brook
and
Tufts University School of Medicine
Nephrology Forum: Nephrotoxicity of contrast media 731
As I review the subject of contrast-associated nephrotoxicity,
I will refer to the patient we are discussing today. He illustrates
many of the important clinical issues and dilemmas that con-
front clinicians caring for patients undergoing contrast-depen-
dent diagnostic and therapeutic procedures. In this Forum, I
will review the clinical aspects of contrast-associated nephro-
toxicity, emphasizing its recognition as a characteristic syn-
drome that occurs in high-risk patients. I will review the
literature pertaining to the pathophysiology of this syndrome
and to recently described animal models of contrast nephrotox-
icity. Finally, I will summarize data on the use of the newer
nonionic contrast agents and their comparative renal toxicity.
Epidemiology and clinical course
The literature on contrast-associated nephrotoxicity does not
reveal the true incidence of the syndrome. Several large retro-
spective studies attest to the relatively low incidence of con-
trast-associated nephrotoxicity following excretory urography,
however. One large retrospective review from the Mayo Clinic
reports no cases of renal failure following excretory urography
in more than 100,000 studies in nondiabetic patients. Among
diabetic patients, the incidence of renal failure was 0.2% [16].
Another large retrospective study, also from the Mayo Clinic,
analyzed the incidence of acute renal failure following aortog-
raphy in 7400 patients; of this group, 8 patients (0.11%) were
referred to nephrologists because of renal failure [17]. Five of
these patients had an elevated baseline creatinine concentration
ranging from 1.4 to 2.2 mg/dl. Additional retrospective studies
report the incidence of contrast-associated renal toxicity to be
less than 1% following either intravenous pyelography or major
arteriography, including cerebral, aortic, and peripheral arteri-
ography [14, 18, 19].
On the other hand, several prospective studies document a
higher incidence of contrast-related renal impairment ranging
from 3.7% to 70% [19—23]. In 12 additional reports, an aggregate
incidence of 10.2% (204/1999) was documented following intra-
venous pyelography and major arteriography [24—35].
What accounts for the variable incidence of nephrotoxicity
among the published clinical reports? Several points are obvi-
ous, including the limitations of retrospective analysis, in which
case detection is contingent on either documentation by
nephrology consultation, or on the availability of renal-function
data both before and after contrast administration. Clearly,
such retrospective analysis tends systematically to underesti-
mate the true incidence of contrast-associated nephrotoxicity.
However, prospective studies also have yielded widely varying
estimates of the incidence of contrast-associated nephrotoxic-
ity, apparently because of differences in patient selection, state
of hydration, rate and site of administration, dose of contrast
agent, and variable definitions of acute renal failure.
In my opinion, the literature amply documents the relative
safety of contrast media as used for intravenous pyelography,
enhanced computerized tomography, and arteriography in the
majority of patients. However, it appears that there is a
subpopulation of patients who have a substantially greater
likelihood of developing contrast-associated nephrotoxicity.
Several authors have tried to identify the factors that increase
the risk of contrast-associated nephrotoxicity [14, 16, 18, 19,21,
25, 36—39]. Table 1 shows the prevalence of such risk factors.
Because many of these risk factors can coexist, it has not been
Table 1. Prevalence of risk factors in patients with contrast-
associated nephrotoxicitya
Risk factors % Prevalence
Azotemia, Cr  1.5 mg/dl 60
Albuminuria, >2+ 56
Hypertension 55
Age, >60 yrs 51
Dehydration 41
Uric acid, >8.0 mgldl 41
Multiple studies 29
Solitary kidney 13
Contrast medium, >2 mI/kg 11
Multiple myeloma 2
0 Data compiled from Refs. 14, 16, 18, 19, 21, 25, 36—39.
possible to determine the independent contribution of each to
the development of renal failure.
Baseline renal insufficiency, usually defined as a serum
creatinine of at least 1.5 mg/dl, predisposes to the development
of further renal impairment following exposure to contrast
medium. In a prospective study of 378 patients undergoing
non-renal angiography, renal failure (defined as an acute in-
crease in serum creatinine of  1.0 mg/dl) developed in only 2%
of patients with a serum creatinine less than 1.5 mg/dl but in
30% of patients with a baseline serum creatinine of at least 1.5
mg/dl [20]. Similarly, in a prospective study of 124 patients
undergoing intravenous urography, an at least 25% increase
above baseline serum creatinine was seen in 15% of patients
with an initial creatinine level of less than 2.0 mg/dl, but in 55%
of those with an initial level of at least 2.0 mg/dl [22]. In 11
studies in which risk factors were tabulated [14, 16, 18, 20—22,
25, 36—39], 60% of patients who developed contrast-associated
nephrotoxicity had pre-existing renal impairment (Table 1).
Underlying renal disease is the most prevalent risk factor.
A more detailed analysis of risk factors was published re-
cently [40]. In 1144 patients undergoing cardiac catheterization
with iopamidol, a nonionic contrast agent, baseline renal insuf-
ficiency was the only confirmed predictor of contrast-associated
nephropathy. At basal serum creatinine levels of 1.1 mgldl or
less, the probability of nephrotoxicity developing was approx-
imately 4%. As basal serum creatinine levels rose, however, the
risk rose exponentially; at levels greater than 2.0 mg/dl, the
probability for developing nephrotoxicity (defined as an acute
increase in creatinine of  0.5 mg/dl) exceeded 20%.
The second most important risk factor appears to be diabetes
mellitus. Prospective as well as retrospective studies have
concluded that diabetic patients are at increased risk of devel-
oping contrast-associated nephrotoxicity [14, 16, 23, 28, 30, 32,
37—39]; many of these studies, however, have focused on
diabetic patients with far advanced renal disease.
How does exposure to radiocontrast media affect the diabetic
patient who has normal or only midly impaired renal function?
In a study of 49 non-dehydrated diabetic patients with serum
creatinine levels of less than 2.0 mg/dl, only 3 (6%) experienced
an increase in basal serum creatinine of at least 25% following
the administration of intravenous contrast material [27]. In this
study, the presence of proteinuria did not appear to predispose
to renal toxicity. In another review of nonazotemic diabetics
(serum creatinine 2.0 mg/dl), 4 of 24 patients (17%) undergo-
ing intravenous pyelography developed renal failure, defined as
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Table 2. Incidence of contrast-induced renal failure in diabetic
patientsa
Creatinine <2.0 mg/dl 11/306 3.6%
Creatinine 2.0—4.0 mg/dl 22/81 27.0%
Creatinine >4,0 mg/dl 30/37 81.0%
a Data from Refs. 19—22, 27, 28, 31, 32, 34, 35, 41.
an increase in serum creatinine of at least 0.2 mg/dl. Of the 16
patients in this group with serum creatinines of less than 1.5
mgldl, only one developed contrast-associated nephrotoxicity
[311. A recently reported prospective study of 85 diabetic
patients without renal insufficiency (mean serum creatinine of
1.0 mg/dl) failed to identify a single episode of renal failure
following exposure to intravascular contrast medium [35].
Azotemic patients with diabetes appear to have a substan-
tially higher incidence of acute renal failure following exposure
to contrast medium than do nonazotemic patients with diabetes
[28, 32, 34, 39]. As Table 2 shows, the literature also suggests
that the incidence of renal failure increases at progressively
higher values of baseline creatinine levels. Data also suggest
that at any given level of azotemia, the diabetic patient is more
likely to experience contrast-associated renal failure than is the
nondiabetic [34, 35]. This hypothesis, however, has not been
evaluated prospectively over large ranges of serum creatinine
values. A recent prospective study found an 8.8% incidence of
renal failure among azotemic diabetics (mean creatinine 2.97
.27 mg/dl), a 3.5% incidence in nondiabetics with similar
degrees of mild renal insufficiency (mean creatinine 2.2 .05
mg/dl), and a 4.5% incidence in nondiabetics with more severe
renal insufficiency (mean creatinine 4.08 .17 mgldl) [35]. As I
previously noted, none of the nonazotemic diabetics experi-
enced renal failure.
Several other potentially important risk factors have been
implicated. Among patients who develop contrast-associated
renal failure, approximately 50% are older than 60 years. This
finding might reflect an increased prevalence of mild or subclin-
ical renal impairment in older patients or a preponderance of
older subjects requiring invasive diagnostic and therapeutic
studies; the latter is certainly the case with cardiac angiography
and coronary angioplasty. Dehydration, a known risk factor in
other causes of acute renal failure, is thought to play a role in
approximately 41% of patients (Table I). This finding calls for
eliminating the routine practice of prohibiting oral fluids and of
using preparatory purgation, especially in the older patient with
either azotemia or diabetes. Other factors frequently encoun-
tered among patients with contrast-associated renal failure are
hypertension, hyperuricemia (uric acid  8.0 mg/dl), and pro-
teinuria ( +2 by dipstick), the latter being yet another marker
for patients with intrinsic renal disease. Additional factors, such
as large contrast loads (> 2 mllkg) and repetitive contrast
studies, as was the case in the present patient, have been
incriminated as risk factors only in some studies and are worthy
of more careful scrutiny in future investigations.
A review of risk factors would not be complete without
mention of multiple myeloma. Early anecdotal reports sug-
gested that patients with myeloma were at high risk for devel-
oping renal failure following the administration of contrast
medium. Subsequent reviews including larger numbers of pa-
tients, however, have reported an aggregate incidence of less
than 5% [42—44]. Additionally, several other factors commonly
encountered in myeloma might predispose the patient to acute
renal failure, including hypercalcemia, hyperuricemia, dehydra-
tion, nephrotoxic antibiotics, light-chain tubulopathy, and renal
amyloidosis. In a study of 14 patients with myeloma and acute
renal failure, only one episode appeared to be related to
radiocontrast medium [42]. Given the numerous individual case
reports, however, it would seem prudent to avoid the use of
contrast agents whenever possible in patients with plasma cell
dyscrasias.
I conclude that renal insufficiency per se predisposes to
contrast-associated nephrotoxicity. The risk is clearly in-
creased in patients with baseline serum creatinine levels of at
least 1.5 mgldl, and may even be increased in those with
baseline levels between 1.1 and 1.5 mgldl. Diabetes mellitus
also is an important risk factor. The azotemic, proteinuric,
diabetic patient, as exemplified by today's patient, clearly is at
high risk for the development of acute renal failure following the
administration of contrast medium. Contrast studies in such
patients should be performed cautiously and only after alterna-
tive imaging techniques that entail less risk have been consid-
ered.
The clinical course of contrast-associated nephrotoxicity
following diverse imaging techniques with a wide variety of
contrast media has been well described [14, 45—47]. Although
nonoliguric renal failure occurs in this setting, approximately
two-thirds of reported cases have been oliguric; moreover, the
oliguria generally is resistant to potent loop diuretics. I should
emphasize that the true incidence of nonoliguric contrast-
associated nephropathy is not known because systematic mon-
itoring of renal function following contrast administration is not
done routinely. The serum creatinine level usually begins to
increase within the first 24 hours after administration of contrast
media and peaks within 96 hours. Serum creatinine levels
generally return to baseline values within 7 to 10 days, but renal
failure requiring short-term or even chronic dialysis is a well-
recognized outcome, particularly in patients whose baseline
serum creatinine levels are greater than 4.0 mg/dl. In a study of
22 patients with advanced renal impairment who underwent
high-dose excretory urography, a 25% decline in creatinine
clearance, from 8.7 mI/mm to 6.6 mI/mm, was documented [48].
All patients experienced a decline in renal function, and 2
patients required chronic dialysis. In these two instances, renal
angiography was performed following urography and before the
creatinine clearance had returned to baseline. Data on 16
non-diabetic patients experiencing acute renal failure following
intravenous pyelogram suggests that if the baseline serum
creatinine is less than 4.0 mg/dl, the peak serum creatinine is
not likely to exceed 8.0 mg/dl and that dialysis is usually not
required [34]. On the other hand, if the baseline creatinine value
is greater than 4.0 mg/dl, peak creatinine levels of greater than
8.0 mgldl often are seen and dialysis is required more fre-
quently. With baseline creatinine values of at least 8.0 mgldl,
renal failure commonly occurs.
Following the administration of contrast material, formed
elements can appear in the urine, including renal tubular
epithelial cells, casts, and debris. These findings are considered
nonspecific and do not correlate with the development of renal
functional alterations [49]. Urate crystals have been reported
frequently and calcium oxalate crystals have been identified
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occasionally [49]. Although heavy proteinuria has been de-
scribed following contrast exposure [50], this finding is unusual.
In most patients with acute tubular necrosis, urine sodium
excretion is greater than 40 mEq/liter, and fractional sodium
excretion (FENa) exceeds 1%. Recent studies, however, have
described paitents with acute renal failure with a low urinary
sodium level and a low fractional excretion of sodium immedi-
ately following exposure to contrast medium. One-third of
patients with renal failure who were tested after receiving
contrast medium had a urinary sodium concentration of less
than 20 mEq/liter [38]. Twelve consecutive patients with con-
trast-associated oliguric renal failure had a fractional excretion
of sodium of less than 1.0% (range, 0.03% to 0.9%) [51]. This
observation is not unique. A low fractional excretion of sodium,
although usually associated with prerenal states or acute gb-
merulonephritis [52], has been described in at least one other
variety of toxic nephropathy, that is, myoglobinuric acute renal
failure [531. Other studies, however, have failed to confirm the
presence of a low fractional excretion of sodium in patients with
contrast-associated nephropathy, so one must question the
sensitivity of this finding [23].
Persistent visualization of the kidneys on plain radiography
24 to 48 hours after the administration of contrast medium has
been thought to be characteristic of contrast nephropathy. In
one study, this finding had a sensitivity of 83% and a specificity
of 93% [54]. Other investigators, however, have described a
high frequency both of false-positive and false-negative findings
[14]. Clearly the most sensitive, specific, and cost-effective
method of making the diagnosis of contrast-associated nephro-
toxicity remains measurement of the serum creatinine level,
obtained 24 to 48 hours following the administration of the
contrast agent. I'll return to the critical importance of measure-
ment of serum creatinine in my discussion of prevention.
The characteristic clinical syndrome of contrast-associated
nephrotoxicity must be considered separate and distinct from
the far less common but more catastrophic syndrome of renal
failure due to cholesterol microemboli. This devastating phe-
nomenon results not from contrast media but from vascular
trauma induced by the catheters used during radiographic study
and during angioplasty. The syndrome is typified by the insid-
ious onset of renal failure following an intra-arterial contrast
study. Renal failure usually progresses over several weeks and
usually is irreversible. Diagnostic findings include livedo retic-
ularis, elevated amylase levels, and peripheral eosinophilia [55].
The urine sediment is remarkably bland. Renal biopsy typically
demonstrates pathognomonic microvascular cholesterol em-
boli.
Pat hophysiology
Although several mechanisms have been suggested (Table 3),
the precise pathogenesis of contrast-associated nephrotoxicity
has not been elucidated. Observed features of the clinical
syndrome, including relatively rapid onset of oliguria, persist-
ent nephrogram, low fractional excretion of sodium, and rapid
resolution of renal failure, all support the notion that a revers-
ible vasoconstrictor mechanism is operative. When contrast
medium is injected directly into the renal artery, both renal
blood flow and glomerular filtration rate abruptly decline [56—
59]. This vasoconstrictor response, following a transient va-
sodilatory phase (Fig. 1), is unique to the renal vascular bed.
The angiotensin II analogue Sarl-A1a8-AII decreases the dura-
tion but not the magnitude of the vasoconstriction; sodium
repletion blunts both the magnitude and duration of the re-
sponse [59]. Intracellular calcium appears to mediate the vaso-
constrictor effect [60]. An infusion of either verapamil, dilt-
iazem, or ethylene glycol-aminoethylether-tetracetic acid (EGTA)
into the renal artery accentuates the contrast-induced initial
vasodilatory phase while attenuating the vasoconstrictor phase;
systemic hemodynamics are not altered. The role that these
maneuvers might play in altering the development of contrast-
associated nephrotoxicity is unknown, largely because a rele-
vant animal model of contrast-induced renal failure was not
available until recently.
Two experimental models have now been introduced and
should help define the pathogenesis of this syndrome as well as
identify useful protective measures. In New Zealand rabbits
maintained for one week on a low-sodium diet, acute renal
failure was consistently produced following administration of
indomethacin (18 mg/kg), and an intravenous infusion of meglu-
mine iothalamate (7 mg/kg). Glomerular filtration rate, as mea-
sured by endogenous creatinine clearance, significantly de-
creased within 24 hours and returned to baseline with 14 days.
Two other groups of rabbits, receiving only contrast medium or
indomethacin, did not experience a comparable decrement in
glomerular filtration rate (Fig. 2) [61]. An acute infusion of
either isotonic saline or isotonic mannitol, beginning one hour
prior to contrast injection and continuing one hour after the
injection, did not protect against the development of acute renal
failure. However, animals given oral isotonic saline and daily
subcutaneous injections of desoxycorticosterone acetate
(DOCA, 1 mg/kg) did not develop acute renal failure following
the administration of indomethacin and contrast medium. Light
Table 3. Possible pathogenetic factors
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Fig. 1. Renal blood flow response to injection of contrast medium in
sodium-deplete and sodium-replete dogs plotted as the change in renal
blood flow (ml/min' g' kidney weight) from baseline flow versus the
time from the bolus injection of contrast medium. (From Ref. 59.)
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Time, days
Fig. 2. Glomerular filtration rate plotted as percentage of control (C)
on days 1,2,3, and 14 following injection of contrast and indomethacin
(N = 12), contrast alone (N = 10), or indomethacin alone (N 9).
*Sjgnjficant difference vs. C. (From Ref. 61.)
microscopy revealed no histologic alterations. Micropuncture
studies disclosed a decrease in single-nephron filtration rate
from 19.55 to 9.54 nI/mm during acute renal failure with an
increase to 17.73 nl/min two weeks later. Proximal tubular
hydrostatic pressure and glomerular capillary pressure, as
estimated by stop-flow pressure, were unchanged. Glomerular
ultrafiltration coefficient (Kr) decreased from 1.28 0.15 to 0.49
0.10 nI/mm/mm Hg following the induction of acute renal
failure. No significant reduction in renal blood flow, as mea-
sured by electromagnetic flow probe, was observed during
induction of acute renal failure. In this model, the reversible
decrease in glomerular filtration induced by indomethacin and
contrast media appeared to result from a reversible decrease in
single-nephron filtration predicated upon a decrease in K, a
decrease that could be prevented with one week of saline and
DOCA but not with an acute infusion of saline or mannitol.
In another animal model [621, salt-depleted uninephrecto-
mized Sabra rats received an acute infusion of indomethacin (10
mg/kg) and sodium iothalamate (6 mI/kg). Within 24 hours
creatinine clearance fell significantly from 0.7 0.1 to 0.2
0.04 mI/mm. This effect was not observed with administration
of indomethacin or contrast medium alone. Histologic studies
revealed necrosis of outer medullary thick ascending limbs
(MTALs), tubular collapse, and casts. Specific cellular damage
included mitrochondrial swelling, nuclear pyknosis, and cyto-
plasmic disruption with intracellular calcification. Areas most
remote from oxygen supply, the deep outer medulla, manifested
the most severe histologic damage. There was excellent corre-
lation between the extent of MTAL injury and the increase in
serum creatinine concentration. Additional findings included
extensive proximal tubular (S1S2) vacuolization, as can be seen
in humans [63]. The investigators speculated that the final
pathway for contrast-induced renal injury in this model might
be medullary hypoxia conditioned by medullary ischemia (due
to volume depletion and prostaglandin inhibition) affecting
metabolically active, hyperfiltering remnant nephrons.
Other studies, both pathologic and physiologic, support a role
for direct tubular toxicity. Histologic alterations including prox-
imal tubular vacuolar transformation, interstitial edema, and
tubular degeneration have been reported [63, 64]. However, the
significance of these findings is unknown because they do not
uniformly correlate with renal dysfunction. Diatrizoate and
iothalamate alter sodium transport in toad bladder [65]. In dogs
[66, 67] and in humans [68], hyperosmolar injection of contrast
medium into the renal artery is associated with a 30% to 50%
decrease in PAH extraction (EPAH). Hyperosmolar control
solutions cause no change in EPAH; the observed decrease in
EPAH might be related to the tri-iodinated molecule. Enzy-
muria, including urinary alkaline phosphatase, LDH, SOOT,
CPK, catalase, and glutathione transferase, has been seen both
in dogs and humans following intra-arterial injection of hyper-
tonic radiocontrast material, mannitol, and saline [69, 70].
Although release of these enzymes suggests cellular injury,
enzyme release does not correlate with functional impairment.
Intratubular precipitation of both urinary protein and uric
acid has been implicated in the pathogenesis of contrast-
associated nephrotoxicity. Early reports of myeloma patients
who sustained renal failure following administration of contrast
medium implicated massive precipitation of Bence Jones pro-
tein with resultant tubular obstruction. Although currently
employed agents might be less likely to cause precipitation of
Bence Jones protein [71], these media have been associated
with in-vitro precipitation of Tamm-Horsfall mucoprotein [72].
Whether such precipitation occurs in vivo is unknown. The
uricosuric properties of contrast media are well known [72—74].
A 64% increase in urinary uric acid-to-creatinine ratio has been
reported following arteriography in patients with underlying
renal insufficiency. Only one patient has been reported with
contrast nephropathy and pathologic changes compatible with
acute urate nephropathy [15]. In one study, administration of
allopurinol over 3 weeks prevented acute hyperuricosuria but
did not prevent renal failure following exposure to contrast
material [75]. In spite of the fact that urinary uric acid-
to-creatinine ratios can exceed 1.0 following contrast adminis-
tration, there is no compelling evidence that uricosuria repre-
sents a major mechanism for the development of contrast-
associated nephrotoxicity.
Contrast agents are known to induce functionally significant
changes in erythrocyte morphology and function, with subse-
quent microcirculatory sludging. Red blood cell crenation and
spherocyte formation leading to erthyrocyte clumping and
sludging with increased blood viscosity have been described in
experimental animals [76—80]. Contrast medium infused directly
into the renal artery of a dog is more toxic, as judged by
histology, when given in blood than when given in saline; this
finding suggests a role for microcirculatory compromise medi-
ated by mechanical red blood cell changes [81]. Tri-iodinated
contrast media cause a leftward shift of the oxyhemoglobin
dissociation curve, both in patients and in vitro [821. How these
changes in red blood cell form and function relate to contrast-
associated nephrotoxicity—if at all—remain unclear.
Severe allergic reactions to radiocontrast agents, including
anaphylaxis and death, are well known. Infusion of contrast
material in the rabbit leads to histamine release, a decrease in
complement, and a fall in microarteriolar pressure [83]. In-vitro
studies demonstrate serotonin release [84], platelet dysfunction
[85], and formation of fibrin degradation products [86]. In one
patient who developed renal failure following exposure to
contrast material, 1gM kappa antibodies against the contrast
medium were detected [87]. Although patients can develop
antibodies to contrast medium [871, the pathophysiologic sig-
nificance of this finding remains unknown.
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In summary, the available literature and recent insights from
two new animal models suggest that contrast-associated neph-
rotoxicity is mediated by renal ischemia and resultant hypoxia
combined with direct cellular toxicity of the iodinated molecule.
Cellular toxicity is increased by both renal insufficiency and
diabetic nephropathy, conditions associated with hyperfiltra-
tion of remnant nephrons and sclerosis of the renal vasculature.
Conditions known to cause vasoconstriction and to interfere
with autoregulation (for example, severe congestive heart fail-
ure, liver failure, volume depletion) could well aggravate the
toxic effects.
Prevention
To date, attempts at preventing contrast-associated nephro-
toxicity have been disappointing. Clearly, given that patients
with elevated baseline serum creatinine levels are at high risk,
avoiding or minimizing exposure to contrast material in such
patients is prudent. Alternate imaging techniques such as ultra-
sonography, magnetic resonance imaging, nuclear imaging, or
computerized axial tomography without contrast media should
be considered. Efforts at avoiding preparatory volume deple-
tion and minimizing contrast volume are rational. When repet-
itive contrast studies cannot be avoided, as with the patient who
underwent coronary angioplasty following coronary angiogra-
phy, serum creatinine values should be allowed to return to
baseline following one study before one proceeds to the next.
Saline infusion has an appealing rationale in minimizing
contrast-associated nephrotoxicity. In one report, success in
preventing renal failure following angiography was attributed to
the administration of 550mlof normal saline per hour during the
radiographic procedure [88].
Mannitol infusion also has been suggested as effective pro-
phylaxis to prevent contrast-associated renal toxicity. Mannitol
infusion prevents ischemic renal failure in the dog [89] and
maintains GFR during controlled renal hypoperfusion in the rat
[90]. An infusion of 500 ml of 5% mannitol prevented a
contrast-induced decline in renal function in 6 patients with
renal insufficiency (mean baseline creatinine, 2.51 mg/dl) [91]. A
comparable group of 5 patients not receiving mannitol experi-
enced a significant increase in serum creatinine, from 2.36 to
3.70 mg/dl, following exposure to a contrast agent. In the largest
study reported to date, 37 patients, all with chronic renal
insufficiency, were given 1500 ml of 0.45% sodium chloride, and
then 250 ml of 20% mannitol within 60 minutes of the procedure
[92]. In 8 patients (22%), serum creatinine increased signifi-
cantly. The authors concluded that mannitol offered protection
because a similar group of 40 unprotected patients experienced
a 70% incidence of renal failure. A recent review recommended
that all patients with a serum creatinine concentration of greater
than 2.0 mgldl be infused with 500 ml of 20% mannitol contain-
ing furosemide, 100 mg for each mg/dl of serum creatinine [93].
The authors recommended that this solution be infused at 20
ml/hr beginning one hour before and continuing for 6 hours after
the procedure. They also recommended that urine output be
replaced with 5% dextrose in water/0.45% sodium chloride
containing 30 mEq of potassium chloride per liter. Unfortu-
nately, no data were offered to support these recommendations.
Despite the absence of firm data, I along with many others
routinely recommend preventive measures including hydration,
minimization of contrast volume, spacing of procedures to
Table 4. Recommended prophylaxisa
Recommendation Number recommending
Hydration 33
Minimize contrast volume 33
Space procedure: allow 33
creatinine to return to
baseline
Discontinue prostaglandin 33
inhibitors
Hypertonic mannitol 26
Furosemide 26
Nonionic media 7
Sodium bicarbonate 5
a Resultsof an informal survey of 33 nephrologists, conducted in 1988
nationally.
Table 5. Properties of selected contrast agents
Osmo-
larity Molec-
Iodine mOs,n/ ular wt $ Cost
mg/dl liter daltons Ig iodine
Ionic agents 0.13—0.18
Hypaque (sodium 300 1500 614
diatrizoate)
Conray (meglumine 282 1217 614
iothalamate)
Renogralin6o 288 1511 614
(sodium/meglumine
diatriazoate)
Conray 400 (sodium 400 1965 614
iothalamate)
Nonionic agents 2.43—3.06
Amipaque (metrizamide) 280 450 789
Isovue (iopamidol) 300 616 777
Amnipaque (iohexol) 300 620 821
allow the serum creatinine to return to its baseline level
between exposures, and administration of furosemide and/or
hypertonic mannitol. Table 4 contains the results of a survey I
conducted of experienced nephrologists regarding their recom-
mendations for prophylaxis of contrast-associated toxicity. A
similar set of recommendations was endorsed in a recent
editorial [94]. Unfortunately, as exemplified by the present
patient, hydration and hypertonic mannitol often fail to prevent
acute renal failure.
New contrast agents
The availability of newer iodinated contrast agents, nonionic
monomers and dimers as well as ionic dimers, has raised the
possibility of reducing or eliminating contrast-related toxicity.
These agents are characterized by an increased number of
iodine atoms per molecule (from 1.5 to 3.0 or 6.0), and thus
have a markedly reduced osmolarity (Table 5). They are of
comparable or improved diagnostic quality and appear to be
associated with fewer side effects. Reductions in the incidence
of local and systemic heat and pain, thrombophlebitis, nausea,
vomiting, hypotension, reduced left ventricular contractile
force, ventricular ectopy, and fibrillation have been reported
[95, 96].
When injected directly into the real artery in an anesthetized
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dog, a biphasic pattern of 10—20 seconds of vasodilation fol-
lowed by a variable period of vasoconstriction is observed both
with diatrizoate and iopamidol. Although pretreatment with
buffered acetylsalicylic acid (10 mg/kg) lowered resting renal
blood flow, it did not affect the previously observed contrast-
induced biphasic fluctuation in renal blood flow, thereby sug-
gesting that the acute hemodynamic alterations in renal blood
flow induced by radiocontrast media are not mediated by
prostaglandins [97]. Unfortunately, prostaglandin metabolites
were not measured in this study.
In a second model using anesthetized dogs [98], in which 20
ml of either diatrizoate or iopamidol was injected directly into
the renal artery, followed by complete balloon occlusion of the
renal artery for 10 minutes, a significant decrease in average
renal cortical blood flow (as measured by radioactive micro-
sphere technique) was observed following infusion of a radio-
contrast agent but not following a saline control. There was no
difference between reductions in blood flow when diatrizoate
was compared with iopamidol. Tubular or glomerular necrosis
was seen in all animals receiving diatrizoate (6/6), in 4 of 6
receiving iopamidol, but also in 2 of 6 receiving a saline control;
thus one can question the significance of the histologic changes
observed.
Proximal tubular vacuolar transformation, so-called "osmot-
ic nephrosis," has been observed following injection of diatri-
zoate, iopamidol, metrizamide, and ioxaglate [99]. These his-
tologic changes, as I previously noted, do not correlate with
renal dysfunction [63]. In a rabbit ear chamber model, metri-
zoate and metrizamide were associated with similar reductions
in microcirculatory velocity [100]. In suspended rabbit proximal
tubule segments [1011, in which cellular injury was evaluated by
alterations in intracellular potassium and calcium, by ATP
depletion, and by basal respiratory rate, diatrizoate had greater
cellular toxicity than did iopamidol. The toxicity was exacer-
bated by hypoxia.
Several clinical reports have concluded that these newer,
nonionic agents are less nephrotoxic than are standard ionic
monomers [102—109]. 1 think these studies are largely inconclu-
sive, however, because they often have focused on patients
with normal renal function, have not always included baseline
creatinine values, and have not uniformly distinguished high-
risk from low-risk individuals. In a recent study of 1144 patients
who were given iopamidol during cardiac catheterization, a
small but significant increase in basal serum creatinine levels
was observed at both 24 and 48 hours after administration of the
contrast agent [40]. An increment in serum creatinine of at least
0.5 mg/dl occurred in 65 patients (6%). As I mentioned previ-
ously, the probability of nephrotoxicity rose exponentially
when the basal creatinine values exceeded 1.1 mg/dl. Another
recent study, in which patients were randomly assigned to
receive either ionic or nonionic contrast for cardiac angiogra-
phy, found no significant difference in the incidence of contrast-
associated nephrotoxicity [110].
We recently completed a prospective non-randomized study
of 71 patients undergoing cardiac angiography with either ionic
(diatrizoate) or nonionic (iopamidol) contrast medium [1111. All
patients had baseline renal insufficiency, that is, a serum
creatinine of at least 1.5 mg/dl. Risk factors, including renal
impairment, diabetes, advanced age, and large contrast volume,
were equally distributed between the two groups. All patients
received 1000 ml of 0.45% sodium chloride prior to angiogra-
phy. Renal failure was defined as an increase in serum creati-
nine of at least 1.0 mg/dl within 48 hours following administra-
tion of the contrast agent, The incidence of contrast-associated
nephrotoxicity was 17% (6/36) in the patients receiving diatri-
zoate and 26% (9/35) in those receiving iopamidol (P 0.35).
One patient required short-term dialysis. Thus, the nephrotox-
icity of nonionic contrast agents has been amply demonstrated.
Moreover, the data suggest that these newer agents are not less
nephrotoxic than are standard preparations, especially in the
high-risk individual with renal impairment and/or diabetic
nephropathy.
Due to the far greater cost of nonionic agents, the debate over
their utilization has received national attention [112]. A recent
report sponsored by the Rand Corporation estimates that
nonionic contrast material, if employed routinely for all con-
trast studies, would represent an aggregate additional annual
expense of $1 billion [113]!
Even more complex and unpredictable than cost consider-
ations are the legal ramifications of using—or not using—the
newer, nonionic media. At what point does failure to utilize a
new technology deviate from ordinary medical practice? Does
an appropriate standard of care include the routine use of
nonionic media, or should only certain high-risk patients re-
ceive these agents? As responsible physicians, we must attempt
to balance what is best for our patients with what is cost
effective. From a nephrologic perspective, I do not think that
the available data on the protective effect of nonionic contrast
media are sufficiently strong to recommend the routine use of
this expensive material, even in patients at high risk for
developing contrast-associated nephrotoxicity.
Questions and answers
DR. ALAN KANTER (Senior Attending Nephrologist, Michael
Reese Hospital, Chicago, Illinois): Is the rapid onset of brisk
diuresis and the speedy recovery of renal function seen in
today's patient described in the literature? Do we have an
explanation for it?
DR. BERNS: Although the literature does describe the prompt
resolution of contrast-induced renal failure in most patients, the
brisk diuresis seen in the patient today is not specifically
referred to. I can only speculate about the mechanism. Perhaps
some of these patients undergo a diuresis during the recovery
phase because of prior hydration and subsequent volume over-
load. Another possibility is excretion of the retained osmoti-
cally active contrast agents, as well as any mannitol that might
have been used. This might have been the case with the patient
presented today.
DR. JORDAN J. COHEN (Dean ofMedicine, State University
of New York at Stony Brook, Stony Brook, New York): How
convincing is the evidence that contrast agents induce actual
cytotoxicity within the tubular epithelium? An alternative ex-
planation, of course, is that these agents induce hemodynamic
changes and cause transient renal failure. Are there any in-vitro
studies using tissue slices, cell suspensions, cell cultures, or the
like that might shed light on whether contrast agents have direct
cellular toxicity?
DR. BERNS: As I previously stated, certain indirect indicators
of cellular damage, such as proximal tubular vacuolization and
increase in urinary enzymes, do not correlate with functional
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impairment. Toad bladder studies demonstrate contrast-related
inhibition of active sodium transport and suggest a direct
cellular effect independent of renal blood flow [65].
In a model of suspended rabbit proximal tubule cells [114],
sodium diatrizoate was associated with alterations in tubule cell
respiration, cation horneostasis, and adenine nucleotide metab-
olism. Under aerobic conditions, administration of 25 millimo-
lar diatrizoate resulted in ATP depletion, an effect increased by
22.5 minutes of hypoxia. When a decrease in tubular potassium
content or an increase in tubular calcium content was used as an
index of cellular toxicity, radiographic contrast was shown to
be toxic. Again, hypoxia increased this toxicity. I think these
data suggest a role for direct cellular toxicity of radiographic
agents. This toxicity probably can be increased by hypoxia or
ischemia; thus a possible interaction exists between direct
cellular factors and hemodynamic factors.
DR. SERAFINO GARELLA (Acting Chairman of Medicine,
Michael Reese Hospital): The similarity between contrast-
associated nephrotoxicity and that associated with nonsteroidal
antiinflammatory agents is striking: the age distribution is the
same; urinary sodium concentration is typically low; spontane-
ous recovery is the rule. This similarity prompts this question:
is there any evidence that contrast agents inhibit prostaglandin
production?
DR. BERNS: The relationship between contrast media and
prostaglandins has been studied in female mongrel dogs [115].
Following an injection of meglumine iothalamate (2.5—3.3 ml!
kg) into the lower thoracic aorta, both glomerular filtration rate
(as measured by endogenous creatinine clearance) and renal
blood flow (as calculated by gamma scintillation ''i hippuran
technique) decreased by approximately 20%. No significant
changes in renal vein or aortic renin angiotensin II levels were
observed. However, renal venous 6-keto-PGF1, a prostacyclin
metabolite, fell significantly; this change was observed at 35
minutes following the contrast injection. Calculated renal se-
cretion rates for 6-keto-PGF,, fell from a baseline value of 8
ng!min toO at 30 minutes and remained depressed as long as 100
minutes following contrast injection. The nadir in secretion of
this prostaglandin metabolite corresponded to a period of
reduction in renal blood flow and creatinine clearance. A causal
relationship between the two has not been established, how-
ever. What role, if any, prostaglandin inhibition plays in clinical
contrast-induced nephropathy is unknown. Based on these data
as well as the observation that pharmacologic prostaglandin
inhibition is a necessary component of the two animal models of
contrast nephrotoxicity I discussed, I recommend that all drugs
known to inhibit prostaglandin synthesis be discontinued prior
to the administration of contrast material.
DR. NORMAN SIMON (Director, Section of Nephrology,
Evanston Hospital, Evanston, Illinois): Many studies that have
addressed the problem of contrast-associated nephropathy have
defined renal failure as a rise in serum creatinine of at least 0.5
mg!dl; in some cases even a smaller number has been used.
Other studies have used the definition that you employed,
namely, a rise of at least 1.0 mg/dl. My question is whether
these kinds of changes really reflect a clinically significant
problem. In other words, if a patient's creatinine rises from 1.5
to 2.5 mgldl and then falls back to 1.5 mg!dl, I would not
consider that to indicate renal failure. What do you believe is a
reasonable way to define this problem?
DR. BERNS: Certainly most patients with a 25% increase in
the serum creatinine value are asymptomatic. However, if
subsequent contrast studies are planned, I recommend that the
creatinine be allowed to return to baseline prior to the admin-
istration of additional radiocontrast material. As in today's
patient, the two episodes of renal failure added significantly to
the overall hospital morbidity as well as to the duration and cost
of the hospitalization. In our prospective study, the mean peak
creatinine level among the 15 patients who developed renal
failure was 4.65 .58 mg!dl; this value represents a clinically
important degree of renal insufficiency. A conservative defini-
tion of contrast-induced acute renal failure is an increase in the
serum creatinine of greater than or equal to 1.0 mgldl within 48
hours following the administration of radiocontrast material.
DR. BRIAN DUFFY (Attending Nephrologist, Michael Reese
Hospital): If the clinical circumstances require a contrast study,
what do you recommend for patients with moderately severe
renal failure, say, those with a serum creatinine greater than 5
mg!dl?
DR. BERNS: By all accounts, you are describing a high-risk
patient. Whenever possible, I recommend avoiding contrast
studies at this level of renal impairment. When such studies
cannot be avoided, however, as is frequently the case with
major arteriography, I recommend that any nonsteroidal anti-
inflammatory agents be stopped well in advance of the study.
Furthermore, I recommend aggressive intravenous hydration,
except, of course, where congestive heart failure exists. I
combine intravenous hydration with the administration of 12.5
to 25.0 g of hypertonic mannitol immediately prior to the
contrast study. When volume overload is a concern, intrave-
nous furosemide can be given either immediately before or
immediately after the contrast agent is administered. Post-
contrast volume depletion can be avoided by routine monitoring
of urinary output and by intravenous fluid replacement as
required. Another potentially useful strategy is minimizing
contrast volume whenever feasible. For example, in patients
undergoing cardiac angiography, a left ventriculogram fre-
quently can be avoided and comparable information obtained
with a multigated nuclear study. Unfortunately, I have no data
generated from randomized, prospective studies to support
these recommendations. I have only clinical experience and
impressions to guide me.
DR. COHEN: What is the frequency with which permanent
renal damage follows exposure to contrast agents? Does such
damage occur in nondiabetics as well as in diabetic patients?
D. BERNS: Permanent renal damage has been documented in
diabetic and nondiabetic patients [29, 34, 48]. Fortunately, it
appears to be a relatively unusual complication cited infre-
quently in the literature. Much of the clinical literature is
characterized by a lack of long-term followup; therefore, the
incidence of permanent renal impairment is not known with
certainty. In this regard, Schwartz and colleagues recom-
mended in 1963 that urography be avoided completely in
patients with advanced renal failure whose creatinine level was
greater than 10 mg!dl [9]. My own experience is that in the vast
majority of patients, creatinine does return to baseline values,
but that in patients whose baseline creatinine values exceed 8
mg!dl, contrast administration carries a high risk for induction
of permanent renal failure requiring dialysis.
DR. COHEN: One feature of this condition seems to be agreed
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on by everyone: ifsome degree of renal insufficiency is already
present, the risk of contrast-associated nephropathy is substan-
tially greater than if renal function is normal to start with. How
do you explain this observation? Why are these patients, even
those with mild degrees of renal insufficiency, so much more
susceptible?
DR. BERNS: I am not sure that we have a definite explanation
for this observation. Perhaps the patient with a diminished
nephron mass experiences a greater load of contrast per func-
tioning nephron with subsequent increased cellular toxicity. An
alternate explanation might involve the presence of underlying
vascular disease in patients with renal parenchymal damage and
subsequent blunting or loss of autoregulation. This would
render the kidney that much more susceptible to any hemody-
namic insult, no matter how transient. This also could explain
the apparent exacerbation of nephrotoxicity in patients with
congestive heart failure, liver failure, and volume depletion, all
conditions known to be associated with compromised renal
autoregulation.
DR. STUART SPRAGUE (RenalFellow, University of Chicago!
Michael Reese Hospital): Patients with severe renal failure, and
even those receiving dialysis, occasionally require a contrast
study. Is it necessary to institute dialysis immediately after such
a study to remove the contrast material from the body?
DR. BERNS: I know of no studies that help us answer this
question. After contrast medium enters the circulation, it dis-
tributes in the extracellular fluid compartment and does not
undergo significant metabolism or biotransformation. The ma-
jor route of excretion is, of course, renal. Therefore one would
anticipate significant retention of contrast medium in the dialy-
sis patient. As a non-protein-bound molecule of middle molec-
ular weight, iodinated contrast material should be removed by
dialysis. The vast majority of dialysis patients tolerate the
retained contrast without apparent complication. Only when
volume overload and pulmonary edema develop do we recom-
mend immediate dialysis following a contrast procedure. We
routinely schedule contrast procedures on nondialysis days. In
well-dialyzed patients, I rarely have had to perform emergency
dialysis to remove the administered contrast agent.
DR. COHEN: You noted that the risk of contrast-associated
nephropathy in diabetic patients with moderate renal insuffi-
ciency is roughly proportional to the serum creatinine level. Is
the same true in nondiabetic patients?
DR. BERNS: I believe so; however, the literature has not
carefully divided patients with widely varying serum creatinine
levels into groups. My own experience indicates that as the
baseline creatinine rises, so does the risk for both the diabetic
and nondiabetic patient.
DR. SIMoN: I am intrigued by the observation that only the
kidney appears to manifest contrast-induced vasoconstriction.
Does the vasoconstriction depend on the site of injection?
DR. BERNS: The intravascular administration of radiographic
contrast material is associated with vasodilation in most vascu-
lar beds. The unique biphasic response of the renal vascular bed
is seen only following injection of contrast material directly into
the renal artery.
DR. KA! LAU (Director, Division of Nephrology, Michael
Reese Hospital): If one used a more sensitive measure of
glomerular filtration rate than serum creatinine—for example,
inulin clearance—and measured GFR systematically before and
after contrast studies in patients with normal renal function,
might one also detect a fall in filtration rate even though serum
creatinine levels might not appear to change?
DR. BERNS: Perhaps a more sensitive measurement of GFR
would detect subtle decrements in GFR in a greater percentage
of patients. Certainly measuring the serum creatinine 24 hours
after a contrast study has its limitations; however, studies on 38
normal individuals using 2-hour creatinine clearance levels
before and immediately after angiography did not demonstrate
a measurable decrement in glomerular filtration rate [49].
Reprint requests to Dr. A. Berns, 55 East Washington, Suite 1100,
Chicago, Illinois 60602, USA
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